Funding for this research was provided by:
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Received: 28 August 2020
Accepted: 25 February 2021
First Online: 10 March 2021
Ethics approval and consent to participate
: The University of North Carolina Institutional Review Board approved all study procedures. The University of North Carolina Institutional Review Board waived the need for consent.
: Not applicable.
: Dr. Wood discloses consulting with Best Doctors, equity with Koneksa Health and Elektra Labs, and honorarium from ASH Research Collaborative. He receives research funding from Pfizer and Genentech. There are no other conflicts of interest to disclose.